Expressive

rs1061235 - HLA-A, POLR1HASP

Magnitude 4.5 · 1 study on file

Reported associations

  • HLA-A★3101 and Carbamazepine-Induced Hypersensitivity Reactions in Europeans - Unknown journal (n.d.) · Unknown authors · PubMed 21428769

    ABSTRACT: BACKGROUND Carbamazepine causes various forms of hypersensitivity reactions, ranging from maculopapular exanthema to severe blistering reactions. The HLA-B★1502 allele has been shown to be strongly correlated with carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN) in the Han Chinese and other Asian populations but not in European populations. METHODS We performed a genomewide association study of samples obtained from 22 subjects with carbamazepine-induced hypersensitivity syndrome, 43 subjects with carbamazepine-induced maculopapular exanthema, and 3987 control subjects, all of European descent. We tested for an association between disease and HLA alleles through proxy single-nucleotide polymorphisms and imputation, confirming associati

Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.

Lifestyle context

Concrete actions anchored to the cited research. We do not prescribe, we describe.

Discuss with your doctor

  • HLA-A*3101 status and carbamazepine safety High

    This SNP is in complete linkage disequilibrium with HLA-A*3101, which confers 9-fold increased risk of carbamazepine hypersensitivity reactions including rash, fever, Stevens-Johnson syndrome, and toxic epidermal necrolysis

    Inform your physician of this genetic finding before starting carbamazepine; request alternative anticonvulsants if medically appropriate

Drug interactions

  • Carbamazepine (anticonvulsant medication) High

    HLA-A*3101 carriers have significantly elevated risk of immune-mediated hypersensitivity reactions to carbamazepine across multiple severity phenotypes

    Use only if alternative anticonvulsants are contraindicated; if prescribed, arrange close clinical monitoring for rash, fever, hepatitis, or systemic symptoms